The board of directors of biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.61 per share of the company's common stock for the second quarter of 2020, it disclosed on Tuesday.
Shareholders of record at the close of business as of 16 March 2020 will receive the dividend on 7 April 2020.
Merck said that for more than a century, it has been providing medicines and vaccines for the most challenging diseases.
The company delivers innovative health solutions such as prescription medicines, vaccines, biologic therapies and animal health products. It operates in more than 140 countries.
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli